Takara Bio Inc.
TS-1(Takara Bio Inc.)은 Pancreatic Cancer Stage III 표적 세포·유전자 치료로, Pancreatic Cancer Stage III; Pancreatic Cancer Stage IV 영역에서 개발·상용화 중입니다. 작용기전: inhibits endometrial cancer cell proliferation, migration, and apoptosis by blocking the PI3K/AKT/mTOR signaling pathway. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 72.2% (ClinicalTrials.gov NCT03382600). 차별점: novel di-sulfa drugs containing 1,3- diaryltriazene derivatives TS (1-13) by conjugation of diazonium salts of primary sulfon.
Pancreatic Cancer Stage III
Pancreatic Cancer Stage III; Pancreatic Cancer Stage IV
Recruiting
CAR-Ts) encoding the CD28 costimulatory endodomain
linker, showed the best inhibitory activity against hCA IX with K i values of 19
retroviral vector to express the CD30-specific CAR (CD30
novel di-sulfa drugs containing 1,3- diaryltriazene derivatives TS (1-13) by conjugation of diazonium salts of primary sulfon
inhibits endometrial cancer cell proliferation, migration, and apoptosis by blocking the PI3K/AKT/mTOR signaling pathway
DNA damage and cell death in cancer cells
biomarkers for diagnosing and understanding TS mechanisms
resistance to acetolactate synthase (ALS)-inhibiting herbicides
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Takara Bio Inc.
TS-1(Takara Bio Inc.)은 Pancreatic Cancer Stage III 표적 세포·유전자 치료로, Pancreatic Cancer Stage III; Pancreatic Cancer Stage IV 영역에서 개발·상용화 중입니다. 작용기전: inhibits endometrial cancer cell proliferation, migration, and apoptosis by blocking the PI3K/AKT/mTOR signaling pathway. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 72.2% (ClinicalTrials.gov NCT03382600). 차별점: novel di-sulfa drugs containing 1,3- diaryltriazene derivatives TS (1-13) by conjugation of diazonium salts of primary sulfon.
Pancreatic Cancer Stage III
Pancreatic Cancer Stage III; Pancreatic Cancer Stage IV
Recruiting
CAR-Ts) encoding the CD28 costimulatory endodomain
linker, showed the best inhibitory activity against hCA IX with K i values of 19
retroviral vector to express the CD30-specific CAR (CD30
novel di-sulfa drugs containing 1,3- diaryltriazene derivatives TS (1-13) by conjugation of diazonium salts of primary sulfon
inhibits endometrial cancer cell proliferation, migration, and apoptosis by blocking the PI3K/AKT/mTOR signaling pathway
DNA damage and cell death in cancer cells
biomarkers for diagnosing and understanding TS mechanisms
resistance to acetolactate synthase (ALS)-inhibiting herbicides
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.